Ranbaxy Laboratories' subsidiary Ranbaxy Australia Pty Ltd (RAPL) has launched atorvastatin 10 mg, 40 mg and 80 mg tablets in the Australian market, after receiving approval from the Therapeutic Goods Administration (TGA), the regulatory authority in Australia. It has introduced the product under the brand name, 'Trovas'. Atorvastatin is the most prescribed statin in Australia and represents the largest patent expiry opportunity ever, in the Australian pharmaceutical market with current market size of around US$ 680 million.

Alex Evans, managing director of RAPL, said, Ranbaxy is privileged to be the first generic company  in Australia to introduce atorvastatin under the brand name 'Trovas'. We remain committed to offering the product at an affordable price that will be beneficial to both the Australian healthcare system, and most importantly, to patients in Australia.”

The company primarily has a portfolio of products covering CNS, CVS, gastro and anti-infectives. RAPL has a distinct business philosophy committed to empowering community pharmacies and improving access to quality medicines. The company has concrete plans to further expand and strengthen its operations in Australia. The continent is an important strategic market for Ranbaxy, which entered the Australian market in November 2006.